Best Buy extends deadline for founder bid






(Reuters) – Best Buy Co Inc agreed to extend the deadline to February 28 for founder Richard Schulze to make a bid for the company, continuing the uncertainty for shareholders over whether he can put a bid together.


Best Buy shares fell 14.2 percent to $ 12.12 on the New York Stock Exchange.






The company said on Friday the extension would allow Schulze to include the consumer electronics retailer’s full-year results as part of his due diligence review.


The new deadline will also give him more time to line up partners and financing for a bid. A source told Reuters on Thursday that Schulze didn’t have financing lined up in time for a December bid.


Schulze, who founded Best Buy in 1966, has said he would fund any deal through a combination of private equity and debt financing, as well as the reinvestment of some of his own equity in the company.


“Obviously with the extension, there is still some hesitation on the part of his private equity suitors about how much financing they would want to put up for this deal,” Morningstar analyst R J Hottovy said.


Under the extension, Schulze will be able to submit an offer any time during February, and the company will have 30 days to review and make a decision on the bid.


In August, Schulze made an informal proposal to acquire Best Buy for $ 24 to $ 26 per share, or a total of $ 8.16 billion to $ 8.84 billion. Including debt, it would be as much as $ 10.9 billion.


But Best Buy’s performance has continued to lag and its stock has slid since. Last month, the company reported a decline in same-store sales for the ninth time in the last 10 quarters.


Best Buy’s fortunes have faltered as consumers increasingly use its big box stores as showrooms for products they end up buying online at Amazon.com Inc and other websites.


To add to its troubles, the company forced out Schulze’s protégé, Brian Dunn, as chief executive earlier this year amid allegations he was having an inappropriate relationship with a female employee.


That scandal led to the ouster of Schulze from the board, and Best Buy hired turnaround expert Hubert Joly as CEO to come up with its own restructuring plan.


Schulze remains Best Buy’s largest shareholder with about one-fifth of the company’s outstanding shares.


If he can come in with a bid at about $ 16 or $ 17 a share when the market thinks the stock is only worth $ 12, it is in the interests of shareholders to extend the deadline, Hottovy said.


Others agreed.


“That’s really the best hope for investors, that Schulze takes it out because there’s been no other good news for the company,” said Rakesh Agrawal, principal analyst at San Francisco-based consulting firm reDesign Mobile.


Agrawal, who also advises hedge funds and money managers on the technology sector, said at this point the stock was trading entirely on whether a deal can get done or not.


A Best Buy spokesman said the extension will not affect the company’s day-to-day operations, especially during the all-important holiday season.


“We are determined to have a strong holiday season,” both in stores and online, spokesman Matt Furman said, adding that the company was moving “full speed ahead” with its turnaround plan.


(Writing by Brad Dorfman; Additional reporting by Olivia Oran in New York, and Siddharth Cavale in Bangalore; Editing by Jeffrey Benkoe)


Business News Headlines – Yahoo! News


Read More..

NKorea rocket launch shows young leader as gambler






PYONGYANG, North Korea (AP) — A triumphant North Korea staged a mass rally of soldiers and civilians Friday to glorify the country’s young ruler, who took a big gamble this week in sending a satellite into orbit in defiance of international warnings.


Wednesday’s rocket launch came just eight months after a similar attempt ended in an embarrassing public failure, and just under a year after Kim Jong Un inherited power following his father’s death.






The surprising success of the launch may have earned Kim global condemnation, but at home the gamble paid off, at least in the short term. To his people, it made the 20-something Kim appear powerful, capable and determined in the face of foreign adversaries.


Tens of thousands of North Koreans, packed into snowy Kim Il Sung Square, clenched their fists in a unified show of resolve as a military band tooted horns and pounded on drums.


Huge red banners positioned in the square called on North Koreans to defend Kim Jong Un with their lives. They also paid homage to Kim Jong Un’s father, Kim Jong Il, and his grandfather, North Korean founder Kim Il Sung.


Pyongyang says the rocket put a crop and weather monitoring satellite into orbit. Much of the rest of the world sees it as a thinly disguised test of banned long-range missile technology. It could bring a fresh round of U.N. sanctions that would increase his country’s international isolation. At the same time, the success of the launch could strengthen North Korea’s military, the only entity that poses a potential threat to Kim’s rule.


The launch’s success, 14 years after North Korea’s first attempt, shows more than a little of the gambling spirit in the third Kim to rule North Korea since it became a country in 1948.


“North Korean officials will long be touting Kim Jong Un as a gutsy leader” who commanded the rocket launch despite being new to the job and young, said Kim Byung-ro, a North Korea specialist at Seoul National University in South Korea.


The propaganda machinery churned into action early Friday, with state media detailing how Kim Jong Un issued the order to fire off the rocket just days after scientists fretted over technical issues, ignoring the chorus of warnings from Washington to Moscow against a move likely to invite more sanctions.


Top officials followed Kim in shrugging off international condemnation.


Workers’ Party Secretary Kim Ki Nam told the crowd, bundled up against a winter chill in the heart of the capital, that “hostile forces” had dubbed the launch a missile test. He rejected the claim and called on North Koreans to stand their ground against the “cunning” critics.


North Korea called the satellite a gift to Kim Jong Il, who is said to have set the lofty goal of getting a satellite into space and then tapped his son to see it into fruition. The satellite, which North Korean scientists say is designed to send back data about crops and weather, was named Kwangmyongsong, or “Lode Star” — the nickname legendarily given to the elder Kim at birth.


Kim Jong Il died on Dec. 17, 2011, so to North Koreans, the successful launch is a tribute. State TV have been replaying video of the launch to “Song of Gen. Kim Jong Il.”


But it is the son who will bask in the glory, and face the international censure that may follow.


Even while he was being groomed to succeed his father, Kim Jong Un had been portrayed as championing science and technology as a way to lift North Korea out of decades of economic hardship.


“It makes me happy that our satellite is flying in space,” Pyongyang citizen Jong Sun Hui said as Friday’s ceremony came to a close and tens of thousands rushed into the streets, many linking arms as they went.


“The satellite launch demonstrated our strong power and the might of our science and technology once again,” she told The Associated Press. “And it also clearly testifies that a thriving nation is in our near future.”


Aside from winning him support from the people, the success of the launch helps his image as he works to consolidate power over a government crammed with elderly, old-school lieutenants of his father and grandfather, foreign analysts said.


Experts say that what is unclear, however, is whether Kim will continue to smoothly solidify power, steering clear of friction with the powerful military while dealing with the strong possibility of more crushing sanctions. The United Nations says North Korea already has a serious hunger problem.


“Certainly in the short run, this is an enormous boost to his prestige,” according to Marcus Noland, a North Korea analyst at the Peterson Institute for International Economics in Washington.


Noland, however, also mentioned the “Machiavellian argument” that this could cause future problems for Kim by significantly boosting the power of the military — “the only real threat to his rule.”


Successfully firing a rocket was so politically crucial for Kim at the onset of his rule that he allowed an April launch to go through even though it resulted in the collapse of a nascent food-aid-for-nuclear-freeze deal with the United States, said North Korea analyst Kim Yeon-su of Korea National Defense University in Seoul.


The launch success consolidates his image as heir to his father’s legacy. But it could end up deepening North Korea’s political and economic isolation, he said.


On Friday, the section at the rally reserved for foreign diplomats was noticeably sparse. U.N. officials and some European envoys stayed away from the celebration, as they did in April after the last launch.


Despite the success, experts say North Korea is years from even having a shot at developing reliable missiles that could bombard the American mainland and other distant targets.


North Korea will need larger and more dependable missiles, and more advanced nuclear weapons, to threaten U.S. shores, though it already poses a shorter-range missile threat to its neighbors.


The next big question is how the outside world will punish Pyongyang — and try to steer North Korea from what could come next: a nuclear test. In 2009, the North conducted an atomic explosion just weeks after a rocket launch.


Scott Snyder, a Korea specialist for the Council on Foreign Relations, wrote recently that North Korea‘s nuclear ambitions should inspire the U.S., China, South Korea and Japan to put aside their issues and focus on dealing with Pyongyang.


If there is a common threat that should galvanize regional cooperation, “it most certainly should be the prospect of a 30-year-old leader of a terrorized population with his finger on a nuclear trigger,” Snyder said.


____


Jon Chol Jin in Pyongyang, and Foster Klug and Sam Kim in Seoul, South Korea, contributed to this report. Follow Jean H. Lee on Twitter: (at)newsjean.


Asia News Headlines – Yahoo! News


Read More..

Verizon Offering $5 Shared 4G Plan for Samsung Galaxy Camera






Imagine the powerful Samsung Galaxy S III smartphone, except that it can’t make phone calls and its backplate has been replaced by a digital camera — handgrip, zoom lens, and all. That’s basically the Samsung Galaxy Camera in a nutshell, and whether it’s a small, awkwardly-shaped Android tablet or a digital camera that you can play Modern Combat 3 on depends on how you look at it.


When the Galaxy Camera launched last month, it was only available in white, and cost $ 499 on AT&T’s network with a month-to-month data plan. But on Dec. 13, it launches on Verizon’s network, in both white and black. The Verizon Galaxy Camera costs $ 50 more up front, but in return it has 4G LTE instead of HSPA+, and Verizon is offering a “promotional price” for the monthly charge: Only $ 5 to add it to a Share Everything plan, instead of the usual $ 10 tablet rate.






A 4G digital camera


While it’s capable of functioning as an Android tablet (or game machine), the biggest reason for the Samsung Galaxy Camera’s 4G wireless Internet is so it can automatically upload photos it takes. Apps such as Dropbox, Photobucket, and Ubuntu One offer a limited amount of online storage space for free, where the Galaxy Camera can save photos without anyone needing to tell it to. Those photos can then be accessed at home, or on a tablet or laptop.


Most smartphones are able to do this already, but few (with the possible exception of the Windows Phone powered Nokia Lumia 920) are able to take photos as high-quality as the Galaxy Camera’s.


Not as good of a deal as it sounds


Dropbox is offering two years’ worth of 50 GB of free online storage space for photos and videos, to anyone who buys a Samsung Galaxy Camera from AT&T or Verizon. (The regular free plan is only 2 GB.)


The problem is, you may need that much space. The photos taken by the Galaxy Camera’s 16 megapixel sensor take up a lot more space, at maximum resolution, than ordinary smartphone snapshots do. Those camera uploads can eat through a shared data plan, and with Verizon charging a $ 15 per GB overage fee (plus the $ 50 extra up-front on top of what AT&T charges) it may make up for the cheaper monthly cost.


On top of that, the Galaxy Camera’s photos are basically on par with a $ 199 digital camera’s — you pay a large premium to combine that kind of point-and-shoot with the hardware equivalent of a high-end smartphone.


It does run Android, though, right?


The Galaxy Camera uses Samsung‘s custom software for its camera app, and lacks a normal phone dialer app. Beyond that, though, it runs the same Android operating system found on smartphones, and can run all the same games and apps.


Some apps don’t work the same on the Galaxy Camera as they do on a smartphone, however. Apps which only run in portrait mode, for instance, require you to hold the camera sideways to use them (especially unpleasant when they’re camera apps). And while it can make voice and even video calls over Skype, it lacks a rear-facing camera or the kind of speaker you hold up close to your ear. So you may end up making speakerphone calls and filming the palm of your hand.


Jared Spurbeck is an open-source software enthusiast, who uses an Android phone and an Ubuntu laptop PC. He has been writing about technology and electronics since 2008.
Linux/Open Source News Headlines – Yahoo! News


Read More..

Documents: Prisoner plotted to kill Justin Bieber






LAS CRUCES, N.M. (AP) — An imprisoned man whose infatuation with Justin Bieber included a tattoo of the pop star on his leg has told investigators in New Mexico he hatched a plot to kill him.


Court documents in a New Mexico district court say Dana Martin told investigators he persuaded a man he met in prison and the man’s nephew to kill Bieber, Bieber’s bodyguard and two others not connected to the pop star.






He told investigators that Mark Staake and Tanner Ruane headed east, planning to be near a Bieber concert scheduled in New York City. They missed a turn and crossed into Canada from Vermont. Staake was arrested on an outstanding warrant. Ruane was arrested later.


The two men face multiple charges stemming for the alleged plot.


Entertainment News Headlines – Yahoo! News


Read More..

More pressure to justify cost of cancer drugs versus benefits






(Reuters) – Medical providers have begun to think more about cost, as well as safety and effectiveness, when they decide on cancer treatments.


In the past, pharmaceutical companies could launch a high-priced drug with little push back. But now, there is more pressure from insurers as well as doctors to justify using drugs that provide only incremental benefits. Products that offer clear-cut advances in treatment, however, still command premium prices.






The pressure on costs is likely to accelerate. The U.S. Affordable Care Act includes several provisions aimed at improving the value of healthcare, including paying hospitals for the quality of care rather than the quantity.


“It’s a sign of the times,” said Mark Mynhier, partner, healthcare industries advisory at PricewaterhouseCoopers PwC. “We are in fact in a significantly financially challenging environment.”


Four-fifths of U.S. health insurers recently polled by PwC now require evidence of cost savings or a clear clinical benefit to include new products on their lists of covered drugs.


Doctors at New York’s Memorial Sloan-Kettering Cancer Center decided in November not to use Zaltrap, a new $ 11,000 a month colon cancer drug, because it has a “modest” impact on survival, works no better than Avastin, a similar but cheaper competitor, and has worse side effects.


Sanofi SA, according to the hospital, responded by offering the drug to all health providers at a 50 percent discount to its wholesale price.


The Manhattan cancer center still does not include Zaltrap on its list of available drugs. Sanofi and Regeneron, which helped develop and also sells the drug, both declined to comment.


“In order to warrant the price, you are going to have to have better overall survival,” said Rhonda Greenapple, chief executive at Reimbursement Intelligence, a consulting firm specializing in medical reimbursement.


Linking value to patient outcomes – mainly a drug’s impact on survival – is particularly important in oncology, where treatment costs can total tens of thousands of dollars a year.


“In cases where there are co-pays, they really do effect the consumer,” Mynhier said. “Patients are saying ‘I can’t afford to pay 10 or 20 percent of a $ 100,000 therapy.’”


WellPoint Inc, the second-largest U.S. health insurer by market value, said it is increasing the amount it pays for less expensive generic cancer drugs as an incentive for doctors to use them.


PROFIT OPPORTUNITY FOR DOCTORS


Infused cancer medications are first purchased by doctors, who then bill insurers for reimbursement. That is different from pills and other oral drugs for which doctors typically write a prescription filled at a pharmacy.


The offer of a 50-percent discount to Zaltrap’s list price is a potential windfall for doctors. Patients, health insurers, the government or anyone else who pays healthcare bills would not see a benefit.


“At the very least it is an incentive for doctors to use the drug,” said Dr Leonard Saltz, chief of Memorial Sloan-Kettering’s gastrointestinal oncology service. “And I find that concerning.”


He noted that rebates and discounts for cancer drugs are not uncommon, but said this is the first time he is aware of a verbal across-the-board offer for a half-price discount.


The average U.S. oncologist, according to the Journal of Oncology Practice, generated revenue of nearly $ 5 million last year, of which drug costs accounted for nearly $ 3 million.


To combat the temptation of wider profit margins, health plans in recent years began reimbursing doctors for cancer drugs based on average sales prices, rather than wholesale prices. But for a new drug such as Zaltrap, reimbursement is based on the full list price until a sales track record is established.


WellPoint said it is raising reimbursements to independent oncologist on a range of generic chemotherapy drugs by as much as 140 percent.


“These drugs are the backbone of many therapies recommended by the National Comprehensive Cancer Network (NCCN) … and typically much less expensive than their brand counterparts,” said Jennifer Malin, WellPoint’s medical director oncology.


She said the goal is to shift the system away from what has been a largely drug-revenue based practice model, to one where oncologists are paid for providing good patient-centered care.


“The payers are looking at the quality data and demanding incremental value over existing products,” said Dan Mendelson, chief executive officer of consulting firm Avalere Health.


“COKE DIDN’T WORK, SO LET’S TRY PEPSI”


Zaltrap was approved in August by the Food and Drug Administration after a study found it improved survival, in combination with chemotherapy, by 1.4 months in colon cancer patients who had stopped responding to chemo.


That is the same benefit seen with Avastin, sold by Roche Holding AG for around $ 5,000 a month, or about half the price of Zaltrap.


NCCN guidelines say either one or the other drug should be used, not both, but Dr Saltz said most Zaltrap use is likely in patients who were already treated with Avastin – a practice that insurers will eventually stop.


“It’s like saying Coke didn’t work so let’s try Pepsi,” he said.


As scientists unravel the biological underpinnings of cancer cells, new targeted therapies are being developed, but the process is expensive.


Dr. Saltz said the solution might just be to walk away from drugs with small, incremental benefits.


“We simply can’t afford to pay these very, very large amounts for drugs that offer most people very small benefit,” Dr Saltz said. “We haven’t figured out how to rein it in.”


(Reporting By Deena Beasley in Los Angeles. Editing by Andre Grenon)


Medications/Drugs News Headlines – Yahoo! News


Read More..

With SolarCity IPO, Elon Musk May Get Clean Tech Right






Over the past few years, Silicon Valley has pumped hundreds of millions of dollars into a vast array of “clean technology” companies. You probably can’t name many of them because, on the whole, they’ve been tremendous failures or totally underwhelming. Companies participating in particularly difficult areas such as solar have turned into laughingstocks and symbols of huge investments gone wrong.


There does, however, seem to be one person getting quite wealthy off green technology, and that’s Elon Musk, the chief executive of Tesla Motors (TSLA) and the chairman of SolarCity (SCTY). When SolarCity began trading on Thursday, its shares jumped more than 50 percent in early trading (although the company had lowered its IPO price in recent days due to lackluster demand). Musk is now the largest shareholder in a pair of public clean-technology companies. (Going into the offering, Musk owned 31 percent of SolarCity, according to a Securities and Exchange Commission filing. That would be worth $ 150.8 million at the $ 8 offering price. A second filing said he intended to buy more shares at the offering.)






“It’s possible that Elon’s two clean-tech companies will be the two most successful clean-tech companies in the U.S.,” said Peter Thiel, the entrepreneur, investor, and Facebook (FB) board member in an interview earlier this year. Thiel is an investor in Musk’s SpaceX venture.


Instead of playing in the cutthroat world of solar-panel production, SolarCity, founded in 2006, focused on leasing solar panels to consumers and businesses and making this process easier. It helps people calculate how much money they can expect to save with solar panels, sets up the financing, and coordinates the installation of the panel. Through the first nine months of the year, SolarCity brought in $ 103 million of sales. Its business has been booming, although the company has yet to turn a profit and is likely to see a number of the state and federal tax credits from which it benefits decline over time.


What makes Musk’s clean-technology empire intriguing are the ways in which he intertwines the businesses. Tesla, for example, has begun building out a network of solar-powered charging stations for its cars. People can drive long distances—San Francisco to Los Angeles, for instance—and refuel their Model S sedans for free using a type of superfast charger. Musk has pledged to keep this refueling service free “forever,” and it is SolarCity that helps set up the stations. Beyond this, Musk plans soon to unveil what he’s describing as a “new mode of transportation” that sounds like some kind of solar-powered, super-fast tunnel called the Hyperloop. (He describes it in some detail here.)


Musk helped come up with the business plan for SolarCity, which was then founded by his cousins, CEO Lyndon Rive and Chief Technology Officer Peter Rive. All the men grew up near each other in Pretoria, South Africa, where Musk led them on a variety of entrepreneurial ventures, including selling Easter eggs door to door. Their mothers were born in Canada, and at about age 15, Musk hatched a plan to move the entire clan to the U.S. after first obtaining Canadian citizenship. “Without Elon I would be stuck in South Africa,” Lyndon told me in an interview earlier this year. “His ability to help us leave the country was amazing.”


Lyndon eventually obtained his green card for the U.S. through his skills as an underwater hockey player. (Yes, this sport exists.) “The U.S. has this green card category for people with exceptional abilities, like if you’re really good at sports or an actor,” Lyndon says. “I’ve been playing the sport since I was 14, and to get the exception you have to prove that you’re one of the best players in the world.” Both Lyndon and his wife have played for the U.S. National Underwater Hockey team.


Once in the U.S., the Rive brothers started a data center software company called Everdream, which Musk bankrolled. Dell (DELL) eventually acquired the company for $ 120 million. The cousins took the money, gave their next venture a think, and all settled on SolarCity.


Both Tesla and SolarCity have their challenges. Tesla has just started pumping out its new Model S sedan at a regular rate. The good news is that it has thousands of back orders to fill. The bad news is that it needs to produce the machines profitability and reliably. Earlier this month, Musk revealed that Tesla had enjoyed a week of positive cash flow. Still, Tesla remains one of the most shorted stocks on the market, with big-time investors betting that Musk will fail. Mitt Romney drove this point home during the presidential debates, describing Tesla as a “loser.”


SolarCity has installed panels at more than 45,000 buildings and been at the forefront of an era when getting this type of technology put on a home or office became much, much easier. “Clean energy has taken a big hit, primarily on the solar side, because of a lot of the companies there were producing a commodity,” Lyndon says, referring to the solar-panel and substrate makers. “The stocks were overhyped because of overdemand and undersupply, and then supply caught up. This should not be a measurement of the market’s willingness to adopt clean energy. The market adoption is almost doubling every year.”


Businessweek.com — Top News


Read More..

Cuban lawmakers meet to consider economy, budget






HAVANA (AP) — Cuban lawmakers are holding the second of their twice-annual sessions with a year-end report expected on the state of the country’s economy.


Legislators are also to approve next year’s budget.






Cuban leaders have sometimes used the parliamentary gatherings to make important announcements or policy statements.


Observers will be watching for word on the progress of President Raul Castro‘s economic reform plan and efforts to promote younger leaders.


The unicameral parliament will reconvene in February with a new membership following elections. It is then expected to name Castro to another five-year term.


State-run media said Castro presided over Thursday’s session.


It was not open to international journalists.


Latin America News Headlines – Yahoo! News


Read More..

AP PHOTOS: Top 10 Search Trends of 2012






NEW YORK (AP) — From the tragic to the downright silly, millions of people searched the Web in 2012 to find out about a royal princess, the latest iPad, a record-breaking skydiver and the death of a pop star.


Google released its 12th annual “zeitgeist” report on Wednesday. The company calls it “an in-depth look at the spirit of the times as seen through the billions of searches on Google over the past year.”






Here’s an Associated Press photo gallery of the top ten trending searches of 2012.


Gadgets News Headlines – Yahoo! News


Read More..

“Lincoln,” “Les Miserables,” “Playbook” lead acting nominations






LOS ANGELES (Reuters) – Hollywood‘s actors cast their net wide on Wednesday, nominating performers from big awards contenders “Lincoln” and musical “Les Miserables” for Screen Actors Guild honors while also singling out the likes of Denzel Washington and Javier Bardem.


“Lincoln,” “Les Miserables” and comedy “Silver Linings Playbook” led the nominations for the SAG awards with four apiece, including the top prize of best movie ensemble cast.






Joining them with two nominations each were the cast of Iranian hostage drama “Argo” and, in a surprise choice, British comedy “The Best Exotic Marigold Hotel.”


The awards from the Screen Actors Guild are among the most-watched honors during Hollywood film awards season leading up to the Academy Awards because actors make up the largest voting group when the Oscars come around in February.


SAG voters focus on performances rather than directing and writing, meaning that action and effects-heavy films like “The Hobbit” are usually sidelined.


Consequently, SAG largely shunned the expected Oscar contender “Zero Dark Thirty” about the U.S. hunt for Osama bin Laden, giving it just one nomination for Jessica Chastain’s performance as a CIA agent.


But the latest James Bond blockbuster “Skyfall” made it onto SAG‘s list, with nominations for its stunt ensemble and Spanish actor Bardem’s supporting turn as blond-haired villain Silva.


Other perceived Oscar-worthy movies, including slavery era Western “Django Unchained,” went unmentioned, while cult drama “The Master” had just one nomination – for actor Philip Seymour Hoffman.


Nicole Kidman made the best supporting actress list for her turn in the steamy but little-seen independent movie “The Paperboy,” while Britain’s Helen Mirren was recognized for her portrayal of Alfred Hitchcock’s long-suffering wife in “Hitchcock.”


The SAG awards will be given out in Los Angeles on January 27 in a live telecast on the TBS and TNT networks.


Golden Globe nominations are announced on Thursday and Oscar nominations will be revealed on January 10.


‘LINCOLN’ PICKS UP STEAM


“Lincoln,” director Steven Spielberg’s well-reviewed film about U.S. President Abraham Lincoln‘s battle to outlaw slavery, has been picking up multiple accolades from U.S. critics in the busy Hollywood awards season.


On Wednesday, it brought SAG nominations for lead actor Daniel Day-Lewis and supporting actors Sally Field as his wife, and Tommy Lee Jones as powerful Congressman Thaddeus Stevens.


Hugh Jackman was nominated for best actor while Anne Hathaway is in the race for her supporting role in the movie adaptation of hit stage musical “Les Miserables.”


Other actors nominated on Wednesday included the stars of quirky comedy “Silver Linings Playbook” – Bradley Cooper, Jennifer Lawrence and Robert DeNiro. John Hawkes and Helen Hunt also have a stake, for playing a disabled man and his sex therapist in heart-warming independent movie “The Sessions.”


“Being recognized by your peers is something I could only dream of happening and to be included in this group of actors is not only humbling but quite frankly, surreal,” Cooper, a first-time SAG nominees, said in a statement.


Washington, a two-time Oscar winner, was nominated for playing an alcoholic pilot in “Flight,” a role that has been largely overlooked in early critics award.


Perhaps the biggest surprise on Wednesday was “The Best Exotic Marigold Hotel,” the story of a group of elderly Britons who retire to a ramshackle Indian hotel.


The film, which boasts a strong British cast including Judi Dench, Tom Wilkinson and Bill Nighy, had two nominations – best ensemble and best supporting actress for Maggie Smith.


Smith also was nominated in SAG‘s television category for her role as a sarcastic countess in period drama “Downton Abbey.”


The popular British show was among the picks for ensemble acting in the TV category.


Other TV drama nominations went to the casts of “Boardwalk Empire,” “Homeland,” “Mad Men” and “Breaking Bad.”


In TV comedy, old favorites “30 Rock,” “Glee,” “The Big Bang Theory,” “Modern Family,” “Nurse Jackie” and “The Office” were nominated for their ensemble casts.


(Editing by Xavier Briand and Bill Trott)


Movies News Headlines – Yahoo! News


Read More..

Lilly plans another study for Alzheimer’s drug






INDIANAPOLIS (AP) — Eli Lilly‘s experimental Alzheimer’s drug has flashed potential to help with mild cases of the disease, but patients and doctors will have to wait a few more years to learn whether regulators will allow the drugmaker to sell it.


Lilly said Wednesday that it will launch another late-stage study of the drug, solanezumab, no later than next year’s third quarter. The company’s stock slipped in midday trading.






The Indianapolis drugmaker said in August that the intravenous treatment failed to slow memory decline in two late-stage studies of about 1,000 patients each. But scientists saw a statistically significant slowing when they combined trial data. Pooled results found 34 percent less mental decline in mild Alzheimer’s patients compared with those on a fake treatment for 18 months.


Researchers also saw a statistically significant result when they examined a subgroup of patients with mild cases of Alzheimer’s disease.


Lilly will attempt to confirm that benefit in the new trial before it seeks U.S. regulatory approval, something analysts widely expected the drugmaker to do after it announced the initial results.


The additional study could help Lilly build a better case with U.S. regulators. But it will likely take a few years to learn the results. Researchers will have to measure over time a patient’s rate of cognitive decline, which involves the ability remember things.


Citi analyst Andrew Baum said in a research note the study will likely be completed by the second half of 2015. He expects the drug, if approved, to launch in 2017.


Eli Lilly and Co.’s share price fell $ 1.60, or 3.2 percent, to close at $ 49. It’s still up 16 percent since the company announced the initial results in August. Baum said Wednesday’s news helped shake out some of the “false hope” for a near-term approval of the drug that had inflated the stock price.


Drugmakers have tried and failed for years to develop successful treatments for Alzheimer’s, and patients and doctors are anxious for something that can slow its progression.


Solanezumab was one of three potential Alzheimer’s drugs in late-stage testing. Bapineuzumab, being developed by Pfizer Inc. and Johnson & Johnson’s Janssen Alzheimer Immunotherapy unit, gave disappointing results in two studies last summer.


A pivotal study of the third — Gammagard, by Baxter International Inc. — will wrap up at the end of this year. Results are expected in the first or second quarter next year.


Solanezumab binds to beta-amyloid protein, which scientists believe is a key component to sticky plaque that basically gums up the brain of a patient with Alzheimer’s disease. The drug is designed to help the body remove the protein from the brain before it can form that plaque.


Current treatments like Pfizer Inc.’s Aricept try to control symptoms of the disease. Analysts have said a treatment that does more than manage symptoms such as memory loss, confusion and agitation could be worth billions of dollars in annual sales. But drugmakers first have to spend a massive amount on testing and clinical development to produce such a drug.


“When you go for the blockbuster, you have to pay for the blockbuster, either in money or time,” WBB Securities analyst Steve Brozak said regarding Lilly’s announcement.


More than 35 million people worldwide have dementia, a term for brain disorders that affect memory, judgment and other mental functions. Alzheimer’s is the most common type. Many Alzheimer’s patients typically live four to eight years after diagnosis, as the disease gradually erodes their memory and ability to think or perform simple tasks.


In the United States, 5.4 million people have Alzheimer’s, which is the country’s sixth-leading cause of death. The number of Alzheimer’s patients in the U.S. is expected to jump to 16 million by 2050, and costs for care are expected to skyrocket.


___


AP Chief Medical Writer Marilynn Marchione in Milwaukee contributed to this report.


Diseases/Conditions News Headlines – Yahoo! News


Read More..